Nephros, Inc. (NASDAQ: NEPH) Stock Competitors & Peer Comparison
See NEPH's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Instruments & Supplies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for NEPH and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| NEPH | $3.64 | -3.45% | 38.6M | 50.86 | $0.07 | N/A |
| BDX | $156.36 | +2.22% | 56.6B | 11.62 | $13.45 | +2.39% |
| BDXA | $59.24 | -2.24% | 55.9B | 45.70 | $1.30 | +2.39% |
| MDLN | $38.75 | +2.98% | 32.8B | 45.06 | $0.86 | N/A |
| WST | $328.20 | -7.67% | 23.2B | 41.19 | $7.97 | +0.26% |
| HOLX | $76.01 | +0.00% | 17B | 31.54 | $2.41 | N/A |
| COO | $70.31 | +0.11% | 13.7B | 15.42 | $4.56 | N/A |
| BDXB | $48.16 | +1.39% | 13.7B | 7.60 | $6.33 | +2.39% |
| BAX | $22.40 | +3.37% | 11.6B | 10.77 | $2.08 | +0.89% |
| ATR | $132.36 | +2.61% | 8.4B | 23.13 | $5.72 | +1.43% |
Stock Comparison
Becton, Dickinson and Company (NYSE: BDX)
NEPH vs BDX Comparison July 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 38.6M. In comparison, BDX has a market cap of 56.6B. Regarding current trading prices, NEPH is priced at $3.64 on the NASDAQ, while BDX trades at $156.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 50.86, whereas BDX's P/E ratio is 11.62. In terms of profitability, NEPH's ROE is +0.08%, compared to BDX's ROE of +0.05%. Regarding short-term risk, NEPH is more volatile compared to BDX. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check BDX's competition here
Becton, Dickinson and Company (NYSE: BDXA)
NEPH vs BDXA Comparison July 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 38.6M. In comparison, BDXA has a market cap of 55.9B. Regarding current trading prices, NEPH is priced at $3.64 on the NASDAQ, while BDXA trades at $59.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 50.86, whereas BDXA's P/E ratio is 45.70. In terms of profitability, NEPH's ROE is +0.08%, compared to BDXA's ROE of +0.05%. Regarding short-term risk, NEPH is more volatile compared to BDXA. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check BDXA's competition here
Medline Inc. (NASDAQ: MDLN)
NEPH vs MDLN Comparison July 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 38.6M. In comparison, MDLN has a market cap of 32.8B. Regarding current trading prices, NEPH is priced at $3.64 on the NASDAQ, while MDLN trades at $38.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 50.86, whereas MDLN's P/E ratio is 45.06. In terms of profitability, NEPH's ROE is +0.08%, compared to MDLN's ROE of +0.07%. Regarding short-term risk, NEPH is more volatile compared to MDLN. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check MDLN's competition here
West Pharmaceutical Services, Inc. (NYSE: WST)
NEPH vs WST Comparison July 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 38.6M. In comparison, WST has a market cap of 23.2B. Regarding current trading prices, NEPH is priced at $3.64 on the NASDAQ, while WST trades at $328.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 50.86, whereas WST's P/E ratio is 41.19. In terms of profitability, NEPH's ROE is +0.08%, compared to WST's ROE of +0.19%. Regarding short-term risk, NEPH is more volatile compared to WST. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check WST's competition here
Hologic, Inc. (NASDAQ: HOLX)
NEPH vs HOLX Comparison July 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 38.6M. In comparison, HOLX has a market cap of 17B. Regarding current trading prices, NEPH is priced at $3.64 on the NASDAQ, while HOLX trades at $76.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 50.86, whereas HOLX's P/E ratio is 31.54. In terms of profitability, NEPH's ROE is +0.08%, compared to HOLX's ROE of +0.11%. Regarding short-term risk, NEPH is more volatile compared to HOLX. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check HOLX's competition here
The Cooper Companies, Inc. (NASDAQ: COO)
NEPH vs COO Comparison July 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 38.6M. In comparison, COO has a market cap of 13.7B. Regarding current trading prices, NEPH is priced at $3.64 on the NASDAQ, while COO trades at $70.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 50.86, whereas COO's P/E ratio is 15.42. In terms of profitability, NEPH's ROE is +0.08%, compared to COO's ROE of +0.03%. Regarding short-term risk, NEPH is more volatile compared to COO. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check COO's competition here
Becton, Dickinson and Company (NYSE: BDXB)
NEPH vs BDXB Comparison July 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 38.6M. In comparison, BDXB has a market cap of 13.7B. Regarding current trading prices, NEPH is priced at $3.64 on the NASDAQ, while BDXB trades at $48.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 50.86, whereas BDXB's P/E ratio is 7.60. In terms of profitability, NEPH's ROE is +0.08%, compared to BDXB's ROE of +0.05%. Regarding short-term risk, NEPH is more volatile compared to BDXB. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check BDXB's competition here
Baxter International Inc. (NYSE: BAX)
NEPH vs BAX Comparison July 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 38.6M. In comparison, BAX has a market cap of 11.6B. Regarding current trading prices, NEPH is priced at $3.64 on the NASDAQ, while BAX trades at $22.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 50.86, whereas BAX's P/E ratio is 10.77. In terms of profitability, NEPH's ROE is +0.08%, compared to BAX's ROE of -0.16%. Regarding short-term risk, NEPH is more volatile compared to BAX. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check BAX's competition here
AptarGroup, Inc. (NYSE: ATR)
NEPH vs ATR Comparison July 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 38.6M. In comparison, ATR has a market cap of 8.4B. Regarding current trading prices, NEPH is priced at $3.64 on the NASDAQ, while ATR trades at $132.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 50.86, whereas ATR's P/E ratio is 23.13. In terms of profitability, NEPH's ROE is +0.08%, compared to ATR's ROE of +0.14%. Regarding short-term risk, NEPH is more volatile compared to ATR. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check ATR's competition here
Avantor, Inc. (NYSE: AVTR)
NEPH vs AVTR Comparison July 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 38.6M. In comparison, AVTR has a market cap of 7.8B. Regarding current trading prices, NEPH is priced at $3.64 on the NASDAQ, while AVTR trades at $11.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 50.86, whereas AVTR's P/E ratio is 13.46. In terms of profitability, NEPH's ROE is +0.08%, compared to AVTR's ROE of -0.10%. Regarding short-term risk, NEPH is more volatile compared to AVTR. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check AVTR's competition here
Repligen Corporation (NASDAQ: RGEN)
NEPH vs RGEN Comparison July 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 38.6M. In comparison, RGEN has a market cap of 7.4B. Regarding current trading prices, NEPH is priced at $3.64 on the NASDAQ, while RGEN trades at $131.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 50.86, whereas RGEN's P/E ratio is 73.31. In terms of profitability, NEPH's ROE is +0.08%, compared to RGEN's ROE of +0.02%. Regarding short-term risk, NEPH is more volatile compared to RGEN. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check RGEN's competition here
Teleflex Incorporated (NYSE: TFX)
NEPH vs TFX Comparison July 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 38.6M. In comparison, TFX has a market cap of 5.8B. Regarding current trading prices, NEPH is priced at $3.64 on the NASDAQ, while TFX trades at $132.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 50.86, whereas TFX's P/E ratio is 12.32. In terms of profitability, NEPH's ROE is +0.08%, compared to TFX's ROE of -0.28%. Regarding short-term risk, NEPH is more volatile compared to TFX. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check TFX's competition here
Bausch + Lomb Corporation (NYSE: BLCO)
NEPH vs BLCO Comparison July 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 38.6M. In comparison, BLCO has a market cap of 5.8B. Regarding current trading prices, NEPH is priced at $3.64 on the NASDAQ, while BLCO trades at $16.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 50.86, whereas BLCO's P/E ratio is 24.88. In terms of profitability, NEPH's ROE is +0.08%, compared to BLCO's ROE of -0.03%. Regarding short-term risk, NEPH is more volatile compared to BLCO. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check BLCO's competition here
Stevanato Group S.p.A. (NYSE: STVN)
NEPH vs STVN Comparison July 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 38.6M. In comparison, STVN has a market cap of 5.4B. Regarding current trading prices, NEPH is priced at $3.64 on the NASDAQ, while STVN trades at $19.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 50.86, whereas STVN's P/E ratio is 31.81. In terms of profitability, NEPH's ROE is +0.08%, compared to STVN's ROE of +0.10%. Regarding short-term risk, NEPH is more volatile compared to STVN. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check STVN's competition here
Merit Medical Systems, Inc. (NASDAQ: MMSI)
NEPH vs MMSI Comparison July 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 38.6M. In comparison, MMSI has a market cap of 4.4B. Regarding current trading prices, NEPH is priced at $3.64 on the NASDAQ, while MMSI trades at $74.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 50.86, whereas MMSI's P/E ratio is 19.01. In terms of profitability, NEPH's ROE is +0.08%, compared to MMSI's ROE of +0.09%. Regarding short-term risk, NEPH is more volatile compared to MMSI. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check MMSI's competition here
ICU Medical, Inc. (NASDAQ: ICUI)
NEPH vs ICUI Comparison July 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 38.6M. In comparison, ICUI has a market cap of 3.9B. Regarding current trading prices, NEPH is priced at $3.64 on the NASDAQ, while ICUI trades at $157.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 50.86, whereas ICUI's P/E ratio is 19.66. In terms of profitability, NEPH's ROE is +0.08%, compared to ICUI's ROE of +0.02%. Regarding short-term risk, NEPH is more volatile compared to ICUI. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check ICUI's competition here
Haemonetics Corporation (NYSE: HAE)
NEPH vs HAE Comparison July 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 38.6M. In comparison, HAE has a market cap of 3.6B. Regarding current trading prices, NEPH is priced at $3.64 on the NASDAQ, while HAE trades at $78.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 50.86, whereas HAE's P/E ratio is 15.86. In terms of profitability, NEPH's ROE is +0.08%, compared to HAE's ROE of +0.11%. Regarding short-term risk, NEPH is more volatile compared to HAE. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check HAE's competition here
DENTSPLY SIRONA Inc. (NASDAQ: XRAY)
NEPH vs XRAY Comparison July 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 38.6M. In comparison, XRAY has a market cap of 2.6B. Regarding current trading prices, NEPH is priced at $3.64 on the NASDAQ, while XRAY trades at $12.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 50.86, whereas XRAY's P/E ratio is 9.04. In terms of profitability, NEPH's ROE is +0.08%, compared to XRAY's ROE of -0.41%. Regarding short-term risk, NEPH is more volatile compared to XRAY. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check XRAY's competition here
LeMaitre Vascular, Inc. (NASDAQ: LMAT)
NEPH vs LMAT Comparison July 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 38.6M. In comparison, LMAT has a market cap of 2.2B. Regarding current trading prices, NEPH is priced at $3.64 on the NASDAQ, while LMAT trades at $95.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 50.86, whereas LMAT's P/E ratio is 37.05. In terms of profitability, NEPH's ROE is +0.08%, compared to LMAT's ROE of +0.16%. Regarding short-term risk, NEPH is more volatile compared to LMAT. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check LMAT's competition here
Pulse Biosciences, Inc. (NASDAQ: PLSE)
NEPH vs PLSE Comparison July 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 38.6M. In comparison, PLSE has a market cap of 2.1B. Regarding current trading prices, NEPH is priced at $3.64 on the NASDAQ, while PLSE trades at $30.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 50.86, whereas PLSE's P/E ratio is -27.48. In terms of profitability, NEPH's ROE is +0.08%, compared to PLSE's ROE of -0.87%. Regarding short-term risk, NEPH is more volatile compared to PLSE. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check PLSE's competition here
AtriCure, Inc. (NASDAQ: ATRC)
NEPH vs ATRC Comparison July 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 38.6M. In comparison, ATRC has a market cap of 1.8B. Regarding current trading prices, NEPH is priced at $3.64 on the NASDAQ, while ATRC trades at $35.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 50.86, whereas ATRC's P/E ratio is 1088.20. In terms of profitability, NEPH's ROE is +0.08%, compared to ATRC's ROE of +0.02%. Regarding short-term risk, NEPH is more volatile compared to ATRC. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check ATRC's competition here
BioLife Solutions, Inc. (NASDAQ: BLFS)
NEPH vs BLFS Comparison July 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 38.6M. In comparison, BLFS has a market cap of 1.5B. Regarding current trading prices, NEPH is priced at $3.64 on the NASDAQ, while BLFS trades at $29.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 50.86, whereas BLFS's P/E ratio is -141.85. In terms of profitability, NEPH's ROE is +0.08%, compared to BLFS's ROE of -0.03%. Regarding short-term risk, NEPH is more volatile compared to BLFS. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check BLFS's competition here
Azenta, Inc. (NASDAQ: AZTA)
NEPH vs AZTA Comparison July 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 38.6M. In comparison, AZTA has a market cap of 1.3B. Regarding current trading prices, NEPH is priced at $3.64 on the NASDAQ, while AZTA trades at $27.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 50.86, whereas AZTA's P/E ratio is 60.82. In terms of profitability, NEPH's ROE is +0.08%, compared to AZTA's ROE of -0.11%. Regarding short-term risk, NEPH is more volatile compared to AZTA. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check AZTA's competition here
Kestra Medical Technologies, Ltd. (NASDAQ: KMTS)
NEPH vs KMTS Comparison July 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 38.6M. In comparison, KMTS has a market cap of 1.2B. Regarding current trading prices, NEPH is priced at $3.64 on the NASDAQ, while KMTS trades at $21.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 50.86, whereas KMTS's P/E ratio is -8.92. In terms of profitability, NEPH's ROE is +0.08%, compared to KMTS's ROE of -0.59%. Regarding short-term risk, NEPH is more volatile compared to KMTS. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check KMTS's competition here
STAAR Surgical Company (NASDAQ: STAA)
NEPH vs STAA Comparison July 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 38.6M. In comparison, STAA has a market cap of 1.2B. Regarding current trading prices, NEPH is priced at $3.64 on the NASDAQ, while STAA trades at $23.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 50.86, whereas STAA's P/E ratio is 41.02. In terms of profitability, NEPH's ROE is +0.08%, compared to STAA's ROE of -0.06%. Regarding short-term risk, NEPH is more volatile compared to STAA. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check STAA's competition here
QuidelOrtho Corporation (NASDAQ: QDEL)
NEPH vs QDEL Comparison July 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 38.6M. In comparison, QDEL has a market cap of 1.1B. Regarding current trading prices, NEPH is priced at $3.64 on the NASDAQ, while QDEL trades at $16.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 50.86, whereas QDEL's P/E ratio is 11.98. In terms of profitability, NEPH's ROE is +0.08%, compared to QDEL's ROE of -0.56%. Regarding short-term risk, NEPH is more volatile compared to QDEL. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check QDEL's competition here
Atrion Corporation (NASDAQ: ATRI)
NEPH vs ATRI Comparison July 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 38.6M. In comparison, ATRI has a market cap of 809.4M. Regarding current trading prices, NEPH is priced at $3.64 on the NASDAQ, while ATRI trades at $459.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 50.86, whereas ATRI's P/E ratio is 64.50. In terms of profitability, NEPH's ROE is +0.08%, compared to ATRI's ROE of +0.08%. Regarding short-term risk, NEPH is more volatile compared to ATRI. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check ATRI's competition here
AngioDynamics, Inc. (NASDAQ: ANGO)
NEPH vs ANGO Comparison July 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 38.6M. In comparison, ANGO has a market cap of 561.7M. Regarding current trading prices, NEPH is priced at $3.64 on the NASDAQ, while ANGO trades at $13.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 50.86, whereas ANGO's P/E ratio is -34.85. In terms of profitability, NEPH's ROE is +0.08%, compared to ANGO's ROE of -0.21%. Regarding short-term risk, NEPH is more volatile compared to ANGO. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check ANGO's competition here
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN)
NEPH vs NNNN Comparison July 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 38.6M. In comparison, NNNN has a market cap of 441.5M. Regarding current trading prices, NEPH is priced at $3.64 on the NASDAQ, while NNNN trades at $9.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 50.86, whereas NNNN's P/E ratio is 145.38. In terms of profitability, NEPH's ROE is +0.08%, compared to NNNN's ROE of +0.27%. Regarding short-term risk, NEPH is more volatile compared to NNNN. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check NNNN's competition here
OraSure Technologies, Inc. (NASDAQ: OSUR)
NEPH vs OSUR Comparison July 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 38.6M. In comparison, OSUR has a market cap of 273.3M. Regarding current trading prices, NEPH is priced at $3.64 on the NASDAQ, while OSUR trades at $3.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 50.86, whereas OSUR's P/E ratio is -4.78. In terms of profitability, NEPH's ROE is +0.08%, compared to OSUR's ROE of -0.21%. Regarding short-term risk, NEPH is more volatile compared to OSUR. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check OSUR's competition here
Sanara MedTech Inc. (NASDAQ: SMTI)
NEPH vs SMTI Comparison July 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 38.6M. In comparison, SMTI has a market cap of 234.2M. Regarding current trading prices, NEPH is priced at $3.64 on the NASDAQ, while SMTI trades at $25.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 50.86, whereas SMTI's P/E ratio is -426.00. In terms of profitability, NEPH's ROE is +0.08%, compared to SMTI's ROE of -2.46%. Regarding short-term risk, NEPH is more volatile compared to SMTI. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check SMTI's competition here
Utah Medical Products, Inc. (NASDAQ: UTMD)
NEPH vs UTMD Comparison July 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 38.6M. In comparison, UTMD has a market cap of 213.8M. Regarding current trading prices, NEPH is priced at $3.64 on the NASDAQ, while UTMD trades at $67.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 50.86, whereas UTMD's P/E ratio is 19.86. In terms of profitability, NEPH's ROE is +0.08%, compared to UTMD's ROE of +0.09%. Regarding short-term risk, NEPH is more volatile compared to UTMD. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check UTMD's competition here
InfuSystem Holdings, Inc. (AMEX: INFU)
NEPH vs INFU Comparison July 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 38.6M. In comparison, INFU has a market cap of 183.9M. Regarding current trading prices, NEPH is priced at $3.64 on the NASDAQ, while INFU trades at $9.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 50.86, whereas INFU's P/E ratio is 23.97. In terms of profitability, NEPH's ROE is +0.08%, compared to INFU's ROE of +0.14%. Regarding short-term risk, NEPH is more volatile compared to INFU. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check INFU's competition here
KORU Medical Systems, Inc. (NASDAQ: KRMD)
NEPH vs KRMD Comparison July 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 38.6M. In comparison, KRMD has a market cap of 175.9M. Regarding current trading prices, NEPH is priced at $3.64 on the NASDAQ, while KRMD trades at $3.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 50.86, whereas KRMD's P/E ratio is -95.75. In terms of profitability, NEPH's ROE is +0.08%, compared to KRMD's ROE of -0.14%. Regarding short-term risk, NEPH is more volatile compared to KRMD. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check KRMD's competition here
Pro-Dex, Inc. (NASDAQ: PDEX)
NEPH vs PDEX Comparison July 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 38.6M. In comparison, PDEX has a market cap of 175.4M. Regarding current trading prices, NEPH is priced at $3.64 on the NASDAQ, while PDEX trades at $54.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 50.86, whereas PDEX's P/E ratio is 19.34. In terms of profitability, NEPH's ROE is +0.08%, compared to PDEX's ROE of +0.29%. Regarding short-term risk, NEPH is more volatile compared to PDEX. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check PDEX's competition here
Microbot Medical Inc. (NASDAQ: MBOT)
NEPH vs MBOT Comparison July 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 38.6M. In comparison, MBOT has a market cap of 77.9M. Regarding current trading prices, NEPH is priced at $3.64 on the NASDAQ, while MBOT trades at $1.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 50.86, whereas MBOT's P/E ratio is -6.58. In terms of profitability, NEPH's ROE is +0.08%, compared to MBOT's ROE of -0.22%. Regarding short-term risk, NEPH is more volatile compared to MBOT. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check MBOT's competition here
Akoya Biosciences, Inc. (NASDAQ: AKYA)
NEPH vs AKYA Comparison July 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 38.6M. In comparison, AKYA has a market cap of 64.4M. Regarding current trading prices, NEPH is priced at $3.64 on the NASDAQ, while AKYA trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 50.86, whereas AKYA's P/E ratio is -1.34. In terms of profitability, NEPH's ROE is +0.08%, compared to AKYA's ROE of -1.80%. Regarding short-term risk, NEPH is more volatile compared to AKYA. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check AKYA's competition here
SkyAI, Inc. (NASDAQ: STSS)
NEPH vs STSS Comparison July 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 38.6M. In comparison, STSS has a market cap of 58.4M. Regarding current trading prices, NEPH is priced at $3.64 on the NASDAQ, while STSS trades at $1.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 50.86, whereas STSS's P/E ratio is -0.02. In terms of profitability, NEPH's ROE is +0.08%, compared to STSS's ROE of -1.66%. Regarding short-term risk, NEPH is more volatile compared to STSS. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check STSS's competition here
Daxor Corporation (NASDAQ: DXR)
NEPH vs DXR Comparison July 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 38.6M. In comparison, DXR has a market cap of 52.7M. Regarding current trading prices, NEPH is priced at $3.64 on the NASDAQ, while DXR trades at $10.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 50.86, whereas DXR's P/E ratio is 27.33. In terms of profitability, NEPH's ROE is +0.08%, compared to DXR's ROE of +0.22%. Regarding short-term risk, NEPH is more volatile compared to DXR. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check DXR's competition here
Singular Genomics Systems, Inc. (NASDAQ: OMIC)
NEPH vs OMIC Comparison July 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 38.6M. In comparison, OMIC has a market cap of 50.8M. Regarding current trading prices, NEPH is priced at $3.64 on the NASDAQ, while OMIC trades at $20.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 50.86, whereas OMIC's P/E ratio is -0.58. In terms of profitability, NEPH's ROE is +0.08%, compared to OMIC's ROE of -0.43%. Regarding short-term risk, NEPH is more volatile compared to OMIC. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check OMIC's competition here
GlucoTrack, Inc. (NASDAQ: IGAP)
NEPH vs IGAP Comparison July 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 38.6M. In comparison, IGAP has a market cap of 50.2M. Regarding current trading prices, NEPH is priced at $3.64 on the NASDAQ, while IGAP trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 50.86, whereas IGAP's P/E ratio is -10.52. In terms of profitability, NEPH's ROE is +0.08%, compared to IGAP's ROE of -0.86%. Regarding short-term risk, NEPH is more volatile compared to IGAP. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check IGAP's competition here
Milestone Scientific Inc. (AMEX: MLSS)
NEPH vs MLSS Comparison July 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 38.6M. In comparison, MLSS has a market cap of 34.5M. Regarding current trading prices, NEPH is priced at $3.64 on the NASDAQ, while MLSS trades at $0.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 50.86, whereas MLSS's P/E ratio is -6.50. In terms of profitability, NEPH's ROE is +0.08%, compared to MLSS's ROE of -1.66%. Regarding short-term risk, NEPH is more volatile compared to MLSS. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check MLSS's competition here
Precision Optics Corporation, Inc. (NASDAQ: POCI)
NEPH vs POCI Comparison July 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 38.6M. In comparison, POCI has a market cap of 33.8M. Regarding current trading prices, NEPH is priced at $3.64 on the NASDAQ, while POCI trades at $4.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 50.86, whereas POCI's P/E ratio is -6.07. In terms of profitability, NEPH's ROE is +0.08%, compared to POCI's ROE of -0.37%. Regarding short-term risk, NEPH is more volatile compared to POCI. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check POCI's competition here
SmileDirectClub, Inc. (NASDAQ: SDC)
NEPH vs SDC Comparison July 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 38.6M. In comparison, SDC has a market cap of 29.1M. Regarding current trading prices, NEPH is priced at $3.64 on the NASDAQ, while SDC trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 50.86, whereas SDC's P/E ratio is -0.03. In terms of profitability, NEPH's ROE is +0.08%, compared to SDC's ROE of -1.96%. Regarding short-term risk, NEPH is less volatile compared to SDC. This indicates lower risk in terms of short-term price fluctuations for NEPH.Check SDC's competition here
Harvard Bioscience, Inc. (NASDAQ: HBIO)
NEPH vs HBIO Comparison July 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 38.6M. In comparison, HBIO has a market cap of 27.3M. Regarding current trading prices, NEPH is priced at $3.64 on the NASDAQ, while HBIO trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 50.86, whereas HBIO's P/E ratio is -16.81. In terms of profitability, NEPH's ROE is +0.08%, compared to HBIO's ROE of -0.73%. Regarding short-term risk, NEPH is more volatile compared to HBIO. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check HBIO's competition here
Invacare Corporation (NYSE: IVC)
NEPH vs IVC Comparison July 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 38.6M. In comparison, IVC has a market cap of 24.9M. Regarding current trading prices, NEPH is priced at $3.64 on the NASDAQ, while IVC trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 50.86, whereas IVC's P/E ratio is -0.79. In terms of profitability, NEPH's ROE is +0.08%, compared to IVC's ROE of -0.46%. Regarding short-term risk, NEPH is more volatile compared to IVC. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check IVC's competition here
Retractable Technologies, Inc. (AMEX: RVP)
NEPH vs RVP Comparison July 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 38.6M. In comparison, RVP has a market cap of 20.4M. Regarding current trading prices, NEPH is priced at $3.64 on the NASDAQ, while RVP trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 50.86, whereas RVP's P/E ratio is -2.06. In terms of profitability, NEPH's ROE is +0.08%, compared to RVP's ROE of -0.08%. Regarding short-term risk, NEPH is more volatile compared to RVP. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check RVP's competition here
Jin Medical International Ltd. (NASDAQ: ZJYL)
NEPH vs ZJYL Comparison July 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 38.6M. In comparison, ZJYL has a market cap of 16M. Regarding current trading prices, NEPH is priced at $3.64 on the NASDAQ, while ZJYL trades at $2.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 50.86, whereas ZJYL's P/E ratio is 12.75. In terms of profitability, NEPH's ROE is +0.08%, compared to ZJYL's ROE of +0.04%. Regarding short-term risk, NEPH is less volatile compared to ZJYL. This indicates lower risk in terms of short-term price fluctuations for NEPH.Check ZJYL's competition here
Femasys Inc. (NASDAQ: FEMY)
NEPH vs FEMY Comparison July 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 38.6M. In comparison, FEMY has a market cap of 11.2M. Regarding current trading prices, NEPH is priced at $3.64 on the NASDAQ, while FEMY trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 50.86, whereas FEMY's P/E ratio is -10.25. In terms of profitability, NEPH's ROE is +0.08%, compared to FEMY's ROE of -2.58%. Regarding short-term risk, NEPH is more volatile compared to FEMY. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check FEMY's competition here
Regentis Biomaterials Ltd. (AMEX: RGNT)
NEPH vs RGNT Comparison July 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 38.6M. In comparison, RGNT has a market cap of 7.8M. Regarding current trading prices, NEPH is priced at $3.64 on the NASDAQ, while RGNT trades at $1.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 50.86, whereas RGNT's P/E ratio is -0.08. In terms of profitability, NEPH's ROE is +0.08%, compared to RGNT's ROE of N/A. Regarding short-term risk, NEPH is more volatile compared to RGNT. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check RGNT's competition here
NanoString Technologies, Inc. (NASDAQ: NSTG)
NEPH vs NSTG Comparison July 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 38.6M. In comparison, NSTG has a market cap of 5.1M. Regarding current trading prices, NEPH is priced at $3.64 on the NASDAQ, while NSTG trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 50.86, whereas NSTG's P/E ratio is -0.03. In terms of profitability, NEPH's ROE is +0.08%, compared to NSTG's ROE of -1.43%. Regarding short-term risk, NEPH is less volatile compared to NSTG. This indicates lower risk in terms of short-term price fluctuations for NEPH.Check NSTG's competition here
NEXGEL, Inc. (NASDAQ: NXGL)
NEPH vs NXGL Comparison July 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 38.6M. In comparison, NXGL has a market cap of 4M. Regarding current trading prices, NEPH is priced at $3.64 on the NASDAQ, while NXGL trades at $0.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 50.86, whereas NXGL's P/E ratio is -1.13. In terms of profitability, NEPH's ROE is +0.08%, compared to NXGL's ROE of -0.70%. Regarding short-term risk, NEPH is more volatile compared to NXGL. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check NXGL's competition here
Predictive Oncology Inc. (NASDAQ: POAI)
NEPH vs POAI Comparison July 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 38.6M. In comparison, POAI has a market cap of 3.6M. Regarding current trading prices, NEPH is priced at $3.64 on the NASDAQ, while POAI trades at $4.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 50.86, whereas POAI's P/E ratio is -0.03. In terms of profitability, NEPH's ROE is +0.08%, compared to POAI's ROE of -107.05%. Regarding short-term risk, NEPH is less volatile compared to POAI. This indicates lower risk in terms of short-term price fluctuations for NEPH.Check POAI's competition here
Lucyd, Inc (NASDAQ: LUCY)
NEPH vs LUCY Comparison July 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 38.6M. In comparison, LUCY has a market cap of 2.6M. Regarding current trading prices, NEPH is priced at $3.64 on the NASDAQ, while LUCY trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 50.86, whereas LUCY's P/E ratio is -0.39. In terms of profitability, NEPH's ROE is +0.08%, compared to LUCY's ROE of -0.83%. Regarding short-term risk, NEPH is more volatile compared to LUCY. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check LUCY's competition here
Meihua International Medical Technologies Co., Ltd. (NASDAQ: MHUA)
NEPH vs MHUA Comparison July 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 38.6M. In comparison, MHUA has a market cap of 2.4M. Regarding current trading prices, NEPH is priced at $3.64 on the NASDAQ, while MHUA trades at $7.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 50.86, whereas MHUA's P/E ratio is 0.25. In terms of profitability, NEPH's ROE is +0.08%, compared to MHUA's ROE of +0.07%. Regarding short-term risk, NEPH is more volatile compared to MHUA. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check MHUA's competition here
NEXGEL, Inc. (NASDAQ: NXGLW)
NEPH vs NXGLW Comparison July 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 38.6M. In comparison, NXGLW has a market cap of 1.8M. Regarding current trading prices, NEPH is priced at $3.64 on the NASDAQ, while NXGLW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 50.86, whereas NXGLW's P/E ratio is -0.06. In terms of profitability, NEPH's ROE is +0.08%, compared to NXGLW's ROE of -0.70%. Regarding short-term risk, NEPH is more volatile compared to NXGLW. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check NXGLW's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVD)
NEPH vs GMVD Comparison July 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 38.6M. In comparison, GMVD has a market cap of 1.8M. Regarding current trading prices, NEPH is priced at $3.64 on the NASDAQ, while GMVD trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 50.86, whereas GMVD's P/E ratio is -0.01. In terms of profitability, NEPH's ROE is +0.08%, compared to GMVD's ROE of +2.09%. Regarding short-term risk, NEPH is less volatile compared to GMVD. This indicates lower risk in terms of short-term price fluctuations for NEPH.Check GMVD's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVDW)
NEPH vs GMVDW Comparison July 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 38.6M. In comparison, GMVDW has a market cap of 1.8M. Regarding current trading prices, NEPH is priced at $3.64 on the NASDAQ, while GMVDW trades at $7.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 50.86, whereas GMVDW's P/E ratio is N/A. In terms of profitability, NEPH's ROE is +0.08%, compared to GMVDW's ROE of +2.09%. Regarding short-term risk, NEPH is less volatile compared to GMVDW. This indicates lower risk in terms of short-term price fluctuations for NEPH.Check GMVDW's competition here
Avinger, Inc. (NASDAQ: AVGR)
NEPH vs AVGR Comparison July 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 38.6M. In comparison, AVGR has a market cap of 1.5M. Regarding current trading prices, NEPH is priced at $3.64 on the NASDAQ, while AVGR trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 50.86, whereas AVGR's P/E ratio is -0.05. In terms of profitability, NEPH's ROE is +0.08%, compared to AVGR's ROE of +17.82%. Regarding short-term risk, NEPH is less volatile compared to AVGR. This indicates lower risk in terms of short-term price fluctuations for NEPH.Check AVGR's competition here
Lucyd, Inc (NASDAQ: LUCYW)
NEPH vs LUCYW Comparison July 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 38.6M. In comparison, LUCYW has a market cap of 296.1K. Regarding current trading prices, NEPH is priced at $3.64 on the NASDAQ, while LUCYW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 50.86, whereas LUCYW's P/E ratio is -0.00. In terms of profitability, NEPH's ROE is +0.08%, compared to LUCYW's ROE of -0.83%. Regarding short-term risk, NEPH is less volatile compared to LUCYW. This indicates lower risk in terms of short-term price fluctuations for NEPH.Check LUCYW's competition here
GlucoTrack, Inc. (NASDAQ: GCTK)
NEPH vs GCTK Comparison July 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 38.6M. In comparison, GCTK has a market cap of 165.2K. Regarding current trading prices, NEPH is priced at $3.64 on the NASDAQ, while GCTK trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 50.86, whereas GCTK's P/E ratio is -0.01. In terms of profitability, NEPH's ROE is +0.08%, compared to GCTK's ROE of -5.82%. Regarding short-term risk, NEPH is less volatile compared to GCTK. This indicates lower risk in terms of short-term price fluctuations for NEPH.Check GCTK's competition here
Apria, Inc. (NASDAQ: APR)
NEPH vs APR Comparison July 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 38.6M. In comparison, APR has a market cap of 0. Regarding current trading prices, NEPH is priced at $3.64 on the NASDAQ, while APR trades at $37.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 50.86, whereas APR's P/E ratio is 22.59. In terms of profitability, NEPH's ROE is +0.08%, compared to APR's ROE of +9.81%. Regarding short-term risk, NEPH is more volatile compared to APR. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check APR's competition here
IntriCon Corporation (NASDAQ: IIN)
NEPH vs IIN Comparison July 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 38.6M. In comparison, IIN has a market cap of 0. Regarding current trading prices, NEPH is priced at $3.64 on the NASDAQ, while IIN trades at $24.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 50.86, whereas IIN's P/E ratio is 226.45. In terms of profitability, NEPH's ROE is +0.08%, compared to IIN's ROE of -0.00%. Regarding short-term risk, NEPH is more volatile compared to IIN. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check IIN's competition here
Analogic Corporation (NASDAQ: ALOG)
NEPH vs ALOG Comparison July 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 38.6M. In comparison, ALOG has a market cap of 0. Regarding current trading prices, NEPH is priced at $3.64 on the NASDAQ, while ALOG trades at $83.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 50.86, whereas ALOG's P/E ratio is 40.93. In terms of profitability, NEPH's ROE is +0.08%, compared to ALOG's ROE of -0.15%. Regarding short-term risk, NEPH is more volatile compared to ALOG. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check ALOG's competition here
Antares Pharma, Inc. (NASDAQ: ATRS)
NEPH vs ATRS Comparison July 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 38.6M. In comparison, ATRS has a market cap of 0. Regarding current trading prices, NEPH is priced at $3.64 on the NASDAQ, while ATRS trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 50.86, whereas ATRS's P/E ratio is 14.95. In terms of profitability, NEPH's ROE is +0.08%, compared to ATRS's ROE of +0.31%. Regarding short-term risk, NEPH is more volatile compared to ATRS. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check ATRS's competition here
Invuity, Inc. (NASDAQ: IVTY)
NEPH vs IVTY Comparison July 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 38.6M. In comparison, IVTY has a market cap of 0. Regarding current trading prices, NEPH is priced at $3.64 on the NASDAQ, while IVTY trades at $7.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 50.86, whereas IVTY's P/E ratio is -3.80. In terms of profitability, NEPH's ROE is +0.08%, compared to IVTY's ROE of -2.40%. Regarding short-term risk, NEPH is more volatile compared to IVTY. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check IVTY's competition here
Hill-Rom Holdings, Inc. (NYSE: HRC)
NEPH vs HRC Comparison July 2026
Nephros, Inc. (NASDAQ: NEPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NEPH stands at 38.6M. In comparison, HRC has a market cap of 0. Regarding current trading prices, NEPH is priced at $3.64 on the NASDAQ, while HRC trades at $155.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NEPH currently has a P/E ratio of 50.86, whereas HRC's P/E ratio is 41.92. In terms of profitability, NEPH's ROE is +0.08%, compared to HRC's ROE of +0.14%. Regarding short-term risk, NEPH is more volatile compared to HRC. This indicates higher risk in terms of short-term price fluctuations for NEPH.Check HRC's competition here